Moderna said yesterday its COVID-19 vaccine booster targetting the BA.1 subvariant of Omicron generated a strong immune response against that variant, with anti-body levels staying high for at least three months.
Omicron-tailored shots by Pfizer and Moderna are already authorised by regulators in several countries. The US has given the go-ahead for booster vaccines that target the currently circulating BA.4 and BA.5 subvariants of Omicron.
“Clinical trial data now indicates that the superior immune response produced by our bivalent booster has durability for at least three months,” Stephane Bancel, Chief Executive Officer, Moderna, said in a statement.
Moderna said it expects data from human trials of its BA.4/BA.5 targetted vaccine later this year.
Edits by EP News Bureau